---
layout: default
title: Acetazolamide
description: "Acetazolamide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 12
evidence_level: L1
indication_count: 10
---

# Acetazolamide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Acetazolamideï¼šå¾é’å…‰çœ¼åˆ©å°¿åˆ°å¿ƒè‚Œç—…è®Šæ¢ç´¢

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Acetazolamide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Acetazolamide åŸæœ¬ç”¨æ–¼é’å…‰çœ¼åŠåˆ©å°¿ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¿ƒè‚Œç—…è®Š (cardiomyopathy)** åŠ**è‚¥åšæ€§å¿ƒè‚Œç—…è®Š (hypertrophic cardiomyopathy)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **3 å€‹è‡¨åºŠè©¦é©—**å’Œ **11 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é’å…‰çœ¼ã€ç™²ç™‡ã€å……è¡€æ€§å¿ƒè¡°ç«­æ°´è…« |
| é æ¸¬æ–°é©æ‡‰ç—‡ | exercise-induced malignant hyperthermiaã€hypertrophic cardiomyopathyã€congenital myopathy with excess of thin filamentsã€hypertrophic cardiomyopathy due to intensive athletic trainingã€distal myopathy, Tateyama typeã€cirrhotic cardiomyopathyã€å¿ƒè‚Œç—…è®Šã€intestinal obstructionã€glycogen storage disease due to acid maltase deficiency, late-onsetã€myopathic intestinal pseudoobstruction |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.83% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 22 å¼µï¼ˆéƒ¨åˆ†å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. exercise-induced malignant hyperthermia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Acetazolamide æ˜¯ç¢³é…¸é…é…¶æŠ‘åˆ¶åŠ‘ï¼Œå‚³çµ±ä¸Šç”¨æ–¼é’å…‰çœ¼å’Œåˆ©å°¿ã€‚è¿‘å¹´ç ”ç©¶ç™¼ç¾å…¶åœ¨æ€¥æ€§å¤±ä»£å„Ÿæ€§å¿ƒè¡°ç«­ä¸­çš„æ‡‰ç”¨åƒ¹å€¼é¡¯è‘—æå‡ã€‚</p>

<p>ADVOR è©¦é©— (2022) é¡¯ç¤ºï¼Œacetazolamide åŠ ä¸Š loop diuretics å¯é¡¯è‘—æ”¹å–„æ€¥æ€§å¿ƒè¡°ç«­æ‚£è€…çš„å»é¬±è¡€æ•ˆæœã€‚å…¶æ©Ÿè½‰åŒ…æ‹¬ï¼š</p>
<ol>
<li>æŠ‘åˆ¶è¿‘ç«¯è…å°ç®¡ç¢³é…¸é…é…¶ï¼Œå¢åŠ éˆ‰é›¢å­æ’æ³„</li>
<li>å…‹æœåˆ©å°¿åŠ‘æŠµæŠ—</li>
<li>èª¿ç¯€é›»è§£è³ªå¹³è¡¡ï¼ˆç‰¹åˆ¥æ˜¯æ°¯é›¢å­ï¼‰</li>

</ol>
<p>å°æ–¼å¿ƒè‚Œç—…è®Šæ‚£è€…ï¼Œå¸¸ä¼´éš¨å¿ƒè¡°ç«­ç—‡ç‹€ï¼Œacetazolamide ä½œç‚ºè¼”åŠ©åˆ©å°¿åŠ‘çš„è§’è‰²å·²ç²è‡¨åºŠé©—è­‰ã€‚æ­¤å¤–ï¼Œ2018 å¹´æ—¥æœ¬å€‹æ¡ˆå ±å‘Šé¡¯ç¤ºï¼Œacetazolamide å¯ç”¨æ–¼æ²»ç™‚è‚¥åšæ€§å¿ƒè‚Œç—…è®Šåˆä½µä½æ°¯è¡€ç—‡æ‚£è€…ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypertrophic cardiomyopathy</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38806171/" target="_blank">38806171</a></td><td>2025</td><td>Article</td><td>ESC heart failure</td><td>2024 update in heart failure.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37169875/" target="_blank">37169875</a></td><td>2023</td><td>Article</td><td>European heart journal. Cardio</td><td>New pharmacological agents and novel cardiovascular pharmacotherapy strategies i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30279861/" target="_blank">30279861</a></td><td>2018</td><td>Article</td><td>Journal of cardiology cases</td><td>Treatment of hypochloremia with acetazolamide in an advanced heart failure patie...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. congenital myopathy with excess of thin filaments</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. hypertrophic cardiomyopathy due to intensive athletic training</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. distal myopathy, Tateyama type</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. cirrhotic cardiomyopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cardiomyopathy</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ3 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05802849" target="_blank">NCT05802849</a></td><td>PHASE4</td><td>RECRUITING</td><td>400</td><td>Acetazolamide Per os for Decompensation of Heart Failure</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06166654" target="_blank">NCT06166654</a></td><td>PHASE4</td><td>RECRUITING</td><td>939</td><td>Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload - A Rand...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06092437" target="_blank">NCT06092437</a></td><td>NA</td><td>RECRUITING</td><td>466</td><td>TAILOR-AHF: Randomized Trial Investigating a Tailored Diuretic Algorithm in Acut...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ10 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38806171/" target="_blank">38806171</a></td><td>2025</td><td>Article</td><td>ESC heart failure</td><td>2024 update in heart failure.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30279861/" target="_blank">30279861</a></td><td>2018</td><td>Article</td><td>Journal of cardiology cases</td><td>Treatment of hypochloremia with acetazolamide in an advanced heart failure patie...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37169875/" target="_blank">37169875</a></td><td>2023</td><td>Article</td><td>European heart journal. Cardio</td><td>New pharmacological agents and novel cardiovascular pharmacotherapy strategies i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/742352/" target="_blank">742352</a></td><td>1978</td><td>Article</td><td>Acta neurologica Scandinavica</td><td>Hypokalaemic periodic paralysis and cardiomyopathy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35619116/" target="_blank">35619116</a></td><td>2022</td><td>Article</td><td>Journal of medical case report</td><td>Congenital hydrocephalus in a trisomy 9p gained child: aÂ case report.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9627326/" target="_blank">9627326</a></td><td>1998</td><td>Article</td><td>Journal of nuclear medicine : </td><td>SPECT findings in mitochondrial encephalomyopathy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29123889/" target="_blank">29123889</a></td><td>2017</td><td>Article</td><td>Acute medicine &amp; surgery</td><td>A case of non-cardiogenic pulmonary edema provoked by intravenous acetazolamide.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22426904/" target="_blank">22426904</a></td><td>2012</td><td>Article</td><td>Saudi medical journal</td><td>The effects of acetazolamide on ischemia reperfused isolated hearts of 2- and 8-...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23571262/" target="_blank">23571262</a></td><td>2014</td><td>Article</td><td>Indian journal of ophthalmolog</td><td>Cystoid macular edema in a patient with Danon disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7324871/" target="_blank">7324871</a></td><td>1981</td><td>Article</td><td>Acta neurologica Scandinavica</td><td>Heart muscle disease in familial hypokalaemic periodic paralysis.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. intestinal obstruction</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.82%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02779803" target="_blank">NCT02779803</a></td><td>N/A</td><td>WITHDRAWN</td><td>0</td><td>STAMCAR: A Prospective EC-IC Bypass Registry</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19653068/" target="_blank">19653068</a></td><td>2009</td><td>Article</td><td>Internal and emergency medicin</td><td>Acetazolamide-induced adynamic ileus.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31383334/" target="_blank">31383334</a></td><td>2019</td><td>Article</td><td>Medical hypotheses</td><td>Hydrocephalus associated with multiple Tarlov cysts.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/13659695/" target="_blank">13659695</a></td><td>1959</td><td>Article</td><td>Ugeskrift for laeger</td><td>[Drug-induced paralytic ileus, with potentiation by rontyl, a chlorothiazide der...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. glycogen storage disease due to acid maltase deficiency, late-onset</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. unclassified intestinal pseudoobstruction</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.79%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è£½å­—ç¬¬007548è™Ÿ | "äººäºº" ä¹™é†¯å¶æ°®èƒºéŒ  | éŒ åŠ‘ | é’å…‰çœ¼åŠæ°´è…«ã€ç™²ç™‡è¼”åŠ©æ²»ç™‚ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027543è™Ÿ | ä¹™é†¯å¶æ°®èƒº | ç²‰åŠ‘ | ç¢³é…¸é…é…¶æŠ‘åˆ¶è—¥ |
| è¡›ç½²è—¥è£½å­—ç¬¬023932è™Ÿ | "æ–°å–œ" å£“ä½œéŒ  | éŒ åŠ‘ | é’å…‰çœ¼ã€å……è¡€æ€§å¿ƒä¸å…¨ä¹‹æ°´è…« |
| è¡›ç½²è—¥è£½å­—ç¬¬007819è™Ÿ | å®‰è³œä»–æ˜éŒ  | éŒ åŠ‘ | é’å…‰çœ¼åŠæ°´è…«ã€ç™²ç™‡è¼”åŠ©æ²»ç™‚ |

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è—¥ç‰©äº¤äº’ä½œç”¨

**Major äº¤äº’ä½œç”¨ï¼š**
- Aspirinï¼ˆé«˜åŠ‘é‡ï¼‰ï¼šå¢åŠ  acetazolamide æ¯’æ€§é¢¨éšªï¼Œå¯èƒ½å¼•èµ·ä»£è¬æ€§é…¸ä¸­æ¯’

**Moderate äº¤äº’ä½œç”¨ï¼š**
- é™è¡€ç³–è—¥ç‰©ï¼ˆå„é¡å£æœé™ç³–è—¥ã€èƒ°å³¶ç´ ï¼‰ï¼šå¯èƒ½å½±éŸ¿è¡€ç³–æ§åˆ¶
- Amphotericin Bï¼šå¢åŠ ä½é‰€è¡€ç—‡é¢¨éšª
- é¡å›ºé†‡ï¼ˆBetamethasoneã€Budesonide ç­‰ï¼‰ï¼šå¢åŠ ä½é‰€è¡€ç—‡é¢¨éšª
- Bisacodylï¼šé›»è§£è³ªå¤±è¡¡é¢¨éšª
- Digoxinï¼šä½é‰€å¯èƒ½å¢åŠ æ¯›åœ°é»ƒæ¯’æ€§
- Lithiumï¼šå¯èƒ½å¢åŠ é‹°æ¯’æ€§
- Metforminï¼šå¯èƒ½å¢åŠ ä¹³é…¸é…¸ä¸­æ¯’é¢¨éšª
- Carbamazepineã€Phenytoinï¼šå¯èƒ½å½±éŸ¿æŠ—ç™²ç™‡è—¥è¡€ä¸­æ¿ƒåº¦
- Topiramateï¼šå¢åŠ ä»£è¬æ€§é…¸ä¸­æ¯’å’Œè…çµçŸ³é¢¨éšª

### ç¦å¿Œç—‡
- ç£ºèƒºé¡è—¥ç‰©éæ•
- åš´é‡è‚åŠŸèƒ½ä¸å…¨
- ä½éˆ‰è¡€ç—‡æˆ–ä½é‰€è¡€ç—‡
- ä»£è¬æ€§é…¸ä¸­æ¯’
- è‰¾è¿ªæ£®æ°ç—‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Acidosis, Respiratory** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Gout** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Acidosis** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦é™ä½åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€è¡€æ “ã€è²§è¡€ã€‚

**Adrenal Insufficiency** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**Glaucoma, Angle-Closure** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Hypokalemia** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**Hyponatremia** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Liver Failure** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½éœ€è¦é™ä½åŠ‘é‡ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
Acetazolamide åœ¨æ€¥æ€§å¤±ä»£å„Ÿæ€§å¿ƒè¡°ç«­çš„è¼”åŠ©åˆ©å°¿è§’è‰²å·²æœ‰é«˜å“è³ª RCT è­‰æ“šæ”¯æŒï¼ˆADVOR è©¦é©—ï¼‰ï¼Œä¸”ç›®å‰æœ‰å¤šå€‹ç¬¬å››æœŸè‡¨åºŠè©¦é©—æ­£åœ¨é€²è¡Œä¸­ã€‚å°æ–¼å¿ƒè‚Œç—…è®Šåˆä½µå¿ƒè¡°ç«­çš„æ‚£è€…ï¼Œacetazolamide å¯ä½œç‚ºå…‹æœåˆ©å°¿åŠ‘æŠµæŠ—çš„æœ‰æ•ˆé¸æ“‡ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å¯†åˆ‡ç›£æ¸¬é›»è§£è³ªï¼ˆç‰¹åˆ¥æ˜¯é‰€ã€éˆ‰ã€æ°¯ã€ç¢³é…¸æ°«æ ¹ï¼‰
- é¿å…èˆ‡é«˜åŠ‘é‡ aspirin ä½µç”¨
- ç›£æ¸¬è…åŠŸèƒ½åŠé…¸é¹¼å¹³è¡¡
- è©•ä¼°æ˜¯å¦æœ‰ç£ºèƒºé¡éæ•å²

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Omalizumab]({{ "/drugs/omalizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Acetazolamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/acetazolamide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_acetazolamide,
  title = {Acetazolamideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/acetazolamide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-21 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
